RxDoctor Payments Data

Oliver James, MD

Pain Medicine · Lexington, KYNPI 1194727701

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.

$4,724in general payments, 2019–2025

Across 179 payments — averaging $26.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$819
  • Globus Medical$488
  • Abbott$384
  • Supernus Pharmaceuticals, Inc.$354
  • Amgen$263
  • Protega Pharmaceutials Inc$252
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,68899%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,724 in reported general payments places this provider in the 55th percentile of 90 pain medicine providers in Kentucky.

See all pain medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$425,303
Medicare patients
600
Services billed
8,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide306$712,615
Xtampza ErOxycodone Myristate522$318,984
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen9,583$197,271
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen6,753$175,306
MovantikNaloxegol Oxalate277$118,184
BelbucaBuprenorphine Hcl179$116,238
OxycontinOxycodone Hcl174$99,893
Oxycodone Hcl2,743$79,337
Gabapentin8,205$78,477
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl831$65,135
Pregabalin1,602$57,806
NucyntaTapentadol Hcl33$47,829
PercocetOxycodone Hcl/Acetaminophen12$39,702
Hysingla ErHydrocodone Bitartrate54$37,329
Morphine Sulfate ErMorphine Sulfate1,193$36,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$238$712,615306 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta$182$483,051734 claims
Redhill Biopharma Inc.Movantik$36$118,184277 claims
AbbVieLinzess, Ubrelvy$248$52,42180 claims
PfizerLyrica$81$10,03311 claims
Almatica Pharma LLCGralise$38$9,81514 claims
Scilex Pharmaceuticals Inc.Ztlido$65$7,90122 claims
Arbor Pharmaceuticals, Inc.Horizant$32$7,44315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 90 pain medicine providers in Kentucky.

Other pain medicine in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →